<DOC>
	<DOC>NCT00857142</DOC>
	<brief_summary>The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.</brief_summary>
	<brief_title>Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>No clinically significant abnormal findings on physical exam, nonmedical history or clinical laboratory results on screening. Positive test results for HIV or hepatitis B or C Treatment for drug or alcohol abuse Allergy to opiates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>